Cornerstone Investment Partners’s Theravance Biopharma TBPH Stock Holding History

Cornerstone Investment Partners’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	+15,348	New	+$254K	0.01%	223

Other funds holding TBPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MCC

Money Concepts Capital Palm Beach Gardens, Florida $2.16B AUM 28.67% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Cornerstone Investment Partners's TBPH Position: Q2 2026 in Review

Cornerstone Investment Partners opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 15,348 shares worth $261K. The stake represents 0.01% of the portfolio and ranks #223 among its holdings.

56 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Cornerstone Investment Partners held 15,348 shares of Theravance Biopharma worth $261K as of Q2 2026.
Theravance Biopharma was a new Cornerstone Investment Partners position in Q2 2026.
Theravance Biopharma made up 0.01% of Cornerstone Investment Partners's portfolio in Q2 2026, its #223 holding.
56 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Cornerstone Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.